Background: With the global rise in viral infections, it is crucial to develop antiviral therapies that are effective across diverse populations. Objective: This study aimed to assess the efficacy of new antiviral therapies in a randomized controlled trial involving multi-ethnic groups. Methods: Participants from Germany, Costa Rica, and Fiji were enrolled, ensuring a diverse sample. They were randomly assigned to receive either the novel antiviral therapy or a placebo for a duration of 12 weeks. Efficacy was measured by viral load reduction and improvement in clinical symptoms. Findings: The antiviral therapy demonstrated a significant reduction in viral load across all groups, with the most notable improvement in the German and Fijian cohorts. Clinical symptoms were alleviated more rapidly in the treatment group compared to the placebo group. Conclusion: The novel antiviral therapy proved to be broadly effective across different ethnic populations, highlighting its potential as a universal treatment option. Further research may explore its long-term efficacy and safety.